Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

Osteonecrosis of the jaw (ONJ) was defined as exposed, necrotic bone in the maxillofacial
region for at least 8 weeks in patients receiving an antiresorptive medication for primary or …

Background Growing evidence has suggested that immune-related genes play crucial roles
in the development and progression of hepatocellular carcinoma (HCC). Nevertheless, the …

Background The main goal of anti-cancer therapy is to specifically inhibit the malignant
activity of cancer cells, while leaving healthy cells unaffected. As such, for every proposed …

Bone-modifying agents (BMAs) are integral to managing patients with advanced cancer.
They improve quality of survival by reducing skeletal-related events, treating …

B7 family members are aberrantly expressed on the human hepatocellular carcinoma (HCC)
cell surface, and induce local and systemic immunosuppression. Tumor-associated …

Nucleic acid-based therapeutics have gained increased attention during recent decades
because of their wide range of application prospects. Immunostimulatory nucleic acids …

This study compiles the main hypotheses involved in the etiopathogenesis of medication-
related osteonecrosis of the jaw (MRONJ). A narrative review of the literature was …

Since the approval of bevacizumab as anti-angiogenic therapy in 2004 by the FDA, an array
of angiogenesis inhibitors have been developed and approved. However, results were …

Small interfering RNAs, depending on their structure, delivery system and sequence, can
stimulate innate and adaptive immunity. The aim of this study was to investigate the …